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AbstrACt
Objectives Adult-onset Still’s disease (AoSd) is a rare 
systemic autoinflammatory disease; its management 
is largely empirical. this is the first clinical study to 
determine if interleukin (IL)-18 inhibition, using the 
recombinant human IL-18 binding protein, tadekinig alfa, 
is a therapeutic option in AoSd.
Methods In this phase II, open-label study, patients 
were ≥18 years with active AoSd plus fever or C reactive 
protein (Crp) levels ≥10 mg/L despite treatment with 
prednisone and/or conventional synthetic disease-
modifying antirheumatic drugs (dMArds). previous 
biological dMArd treatment was permitted. patients 
received tadekinig alfa 80 mg or 160 mg subcutaneously 
three times per week for 12 weeks; those receiving 
80 mg not achieving early predicted response criteria 
(reduction of ≥50% Crp values from baseline and fever 
resolution) were up-titrated to 160 mg for a further 12 
weeks. the primary endpoint was the occurrence of 
adverse events (AEs) throughout the study.
results ten patients were assigned to receive 80 mg 
tadekinig alfa and 13 patients to the 160 mg dose. 
one hundred and fifty-five treatment-emerging AEs 
were recorded, and 47 were considered related to the 
study drug. Most AEs were mild and resolved after drug 
discontinuation. three serious AEs occurred, one possibly 
related to treatment (toxic optic neuropathy). At week 
3, 5 of 10 patients receiving 80 mg and 6 of 12 patients 
receiving 160 mg achieved the predefined response 
criteria.
Conclusions our results indicate that tadekinig alfa 
appears to have a favourable safety profile and is 
associated with early signs of efficacy in patients with 
AoSd.
trial registration number nCt02398435.
IntrOduCtIOn
Adult-onset Still’s disease (AOSD) is a rare non-fa-
milial, non-monogenic systemic inflammatory 
disease, the aetiology and pathogenesis of which 
remain unknown.1 2 AOSD belongs to the group 
of autoinflammatory disorders characterised by 
excessive innate immune responses. AOSD shares 
many similarities with systemic-onset juvenile idio-
pathic arthritis (SoJIA), but is approximately 10 
times less frequent than its juvenile counterpart.1 3 
The course of AOSD is heterogeneous with patients 
experiencing a monocyclic phase with complete 
resolution, and others with persisting or recur-
rent bouts of arthritis and systemic inflammation.4 
The management of AOSD is largely empirical 
and includes the use of non-steroidal anti-inflam-
matory drugs (NSAIDs), systemic glucocorticoids 
and conventional synthetic (cs) disease-mod-
ifying anti-rheumatic drugs (DMARDs), such 
as methotrexate (MTX).5 Randomised clinical 
trials in SoJIA have demonstrated the efficacy 
of anticytokine therapies, including interleukin 
(IL)-1 and IL-6 antagonists.6 7 Similar strategies 
are used in AOSD, although the data are more 
scarce, including mainly retrospective studies,8–11 
and only one randomised open clinical trial.12 
The IL-1 antagonist, canakinumab, is indicated 
for the treatment of AOSD in patients who have 
responded inadequately to previous therapy with 
NSAIDs and systemic corticosteroids13; however, 
results from controlled clinical studies are not 
currently available.
IL-18 has been considered to play a major 
role among the inflammatory agents involved in 
AOSD pathogenesis.14 IL-18 is a proinflammatory 
cytokine of the IL-1 family that is produced by 
various cell types, including monocytes/macro-
phages.15 The biological activity of IL-18 is tightly 
controlled by IL-18 binding protein (IL-18BP), 
a naturally occurring inhibitor that binds IL-18 
with high affinity.16 In AOSD, circulating levels 
of IL-18 were associated with clinical status 
and laboratory markers of disease activity.17 18 
However, currently used immunoassays do not 
distinguish IL-18 complexed with IL-18BP (inac-
tive) and unbound free IL-18 (active). Recently, 
by using a novel immunoassay that selectively 
measured biologically active IL-18, we showed 
that serum levels of free IL-18 were elevated in 
AOSD and correlated with clinical and biolog-
ical markers of disease activity.19 The aim of the 
current study was to determine the safety and effi-
cacy of blocking IL-18 with the administration of 
recombinant human IL-18BP (tadekinig alfa) in 
the treatment of AOSD. This clinical trial was the 
first to determine if IL-18 inhibition is a thera-
peutic option in AOSD.
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MetHOds
study participants
The study ( ClinicalTrials. gov, number NCT02398435) was 
conducted between March 2015 and July 2016. Eligible patients 
were age 18 or older at baseline with AOSD according to the 
Yamaguchi criteria.20 Patients had active disease at baseline as 
defined by the presence of at least two Yamaguchi criteria at the 
screening visit plus either fever or elevated serum levels of C reac-
tive protein (CRP ≥10 mg/L) despite being treated with predni-
sone at ≥5 mg daily for more than 1 month and/or csDMARDs 
(MTX at a dose of 10 mg per week for ≥3 months). Previous 
treatment with synthetic or biological DMARDs (bDMARDs) 
was allowed. All bDMARDs had to be discontinued before base-
line, respecting specific washout periods (described in the online 
supplementary materials). Concomitant use of NSAIDs, predni-
sone and csDMARDs was allowed during the study. Specifically, 
the prednisone daily dosage could be maintained or tapered, but 
any increase was considered as treatment failure. Other inclusion 
and exclusion criteria are described in the online supplementary 
materials.
All patients provided written informed consent before study 
participation. The protocol, informed consent and any accom-
panying material were approved by the ethics committees or 
institutional review board at each centre before study initiation.
study design
This international, multicentre, open-label, dose-escalating 
phase II study included patients from 20 centres in Switzerland, 
France and Germany. Patients were subdivided into two groups 
that were sequentially treated with subcutaneous injections of 
either 80 mg or 160 mg tadekinig alfa three times per week for 
12 weeks. Tadekinig alfa was available at a concentration of 
80 mg/mL. Two injections of 80 mg tadekinig alfa were given to 
patients receiving tadekinig alfa at a dose of 160 mg. All injec-
tions were administered by trained study nurses throughout the 
study period. After the first five patients were assigned to the 
80 mg group, and after the independent Data Safety Monitoring 
Board (DSMB) approval, patients were randomly assigned 1:1 
to receive either 80 mg or 160 mg tadekinig alfa. Allocation to 
receive 80 mg was terminated after the 10th patient was enrolled 
into this group. The decision to continue with the study drug and 
to up-titrate to a higher dose was at the discretion of the DSMB. 
Early predicted criteria of response at 3 weeks were normalisa-
tion of body temperature and decrease by 50% of the baseline 
CRP levels or normalisation of CRP values to <5 mg/L. Response 
to therapy at 12 weeks was predefined as an improvement of 
joint count (both Swollen Joint Count (SJC) and Tender Joint 
Count (TJC) according to a 44-joint assessment) by ≥20% from 
baseline values, and a 70% decrease of CRP levels compared 
with baseline values (or reduction to normal levels) or normali-
sation of ferritin.
After 3 weeks, patients receiving tadekinig alfa 80 mg who did 
not achieve early predicted criteria of response were up-titrated 
to the 160 mg dose for a further 12 weeks of treatment. Dose 
increases to 160 mg for the 80 mg group, or to 320 mg for the 
160 mg group, were also allowed after 3 weeks. A third group, 
320 mg, was planned to be included within the study; however, 
it was decided not to enrol patients into this group since early 
efficacy was achieved in the 80 mg and 160 mg groups. Any 
dose increases from 80 mg to 160 mg or 160 mg to 320 mg were 
made at the treating physician’s discretion. Enrolled patients 
continued treatment through week 16, with a 4-week safety 
follow-up.
Assessments
Patients had regular scheduled visits at baseline (first tadekinig 
alfa administration) and weeks 1, 3, 6, 12 and 16.
The primary endpoint was the occurrence of adverse events 
(AEs) that were recorded throughout the study. The incidence, 
nature and severity of AEs, and abnormal laboratory tests were 
reported.
Secondary endpoints comprised clinical and biological signs 
of efficacy, including the evolution of body temperature, skin 
rash, number of SJC and TJC, patient global assessment, physi-
cian global assessment, pain assessment on a visual analogue 
scale (VAS), fatigue assessment on the VAS and dosage of pred-
nisone with respect to baseline. Laboratory assessments included 
serum levels of CRP, serum amyloid A (SAA), ferritin, free 
IL-18, IL-6, tumour necrosis factor, IL-1 receptor antagonist 
(IL-1Ra), S100A8/9, S100A12 and blood leucocyte and granulo-
cyte counts. All laboratory tests were performed in a centralised 
laboratory (MLM Medical Labs GmbH, Moenchengladbach, 
Germany; see online supplementary materials).
A small pharmacokinetic study was also performed (see online 
supplementary materials).
statistical analysis
For AEs, the statistical analyses were descriptive and the reports 
included standard summary tables (including mean, SD, median, 
minimum, maximum or counts/percentages).
For secondary endpoints, to better assess efficacy, we used 
per-protocol analyses by imputing missing values only from 
week 6 to week 12 (last observation carried forward). If patients 
stopped earlier, they were excluded from the analyses. Contin-
uous variables were compared over time using Wilcoxon signed-
rank test and across dosages using Wilcoxon rank-sum test. 
Categorical variables were compared over time using exact 
McNemar’s test and across dosages using Fisher’s exact test. All 
analyses and tabulations were performed using R V.3.4.1.
results
Twenty-three of the 32 screened patients were included in the 
study. Ten and 13 patients were assigned to receive doses of 
either 80 mg (group 1) or 160 mg (group 2) tadekinig alfa three 
times per week, respectively (figure 1). The baseline character-
istics of the patients included in the two groups are described in 
table 1. In the overall study population of 23 patients, arthritis 
and arthralgia (SJC and TJC) were present in 19 patients at base-
line, neutrophilia in 14 patients, skin rash in 13 patients and 
fever in only 2 patients. Six patients had an early disease onset 
within 6 months prior to study inclusion, whereas all others had 
either chronic or polycyclic courses. Twenty-two patients had 
previously received glucocorticoids up to a median dose (IQR of 
30 mg daily, 8.5–47.5). Thirteen patients had at least one course 
of treatment with a csDMARD and nine patients with at least 
one biological agent. One patient had received no prior gluco-
corticoids or csDMARDs. During the study, 21 patients received 
concomitant glucocorticoids at a median (IQR) baseline pred-
nisone dosage of 15 mg daily (7.5–20), and 9 patients received 
a concomitant csDMARD, including 7 patients treated with 
MTX at a median (IQR) dosage of 17.5 mg weekly (15–22.5). 
By chance, patients recruited in group 2 were younger (35 vs 
49.5 years) with shorter disease duration (11.6 vs 25.5 months) 
and lower prednisone daily dose (15 vs 35 mg) than in group 1.
One patient from group 2 discontinued after 1 week of therapy 
due to an injection site reaction (ISR) and was excluded from the 
efficacy analysis.
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safety analyses
The description of AEs by System Organ Class is shown in 
table 2. One hundred and fifty-five treatment-emergent AEs 
were recorded; 47 were considered related to the study drug 
by the treating physicians. ISRs, upper airway infections and 
arthralgia were the most common AEs. Three and 10 patients 
showed manifestations of local ISRs in groups 1 and 2, respec-
tively. Some patients had more than one episode and most were 
considered mild. Two patients in group 2 had moderately severe 
ISR.
Three serious AEs (SAEs) occurred during the study; two were 
considered, by the treating physicians, as not related to tadekinig 
alfa (one episode of gastroenteritis and one severe back pain due 
to spondylolisthesis) and one as possibly related (toxic optic 
neuropathy). Case details of the toxic optic neuropathy SAE are 
provided within the online supplementary materials.
AEs led to the permanent discontinuation of the study in four 
patients, including three cases of ISR, one with 80 mg and two 
with 160 mg tadekinig alfa doses, respectively, and one case of 
SAE due to toxic optic neuropathy (details within the online 
supplementary materials). The patient who was up-titrated from 
160 mg to 320 mg tadekinig alfa experienced no AE besides mild 
ISR.
efficacy analyses
Among the patients available for clinical evaluation, five patients 
treated with the 80 mg dose (group 1), and six patients treated 
with the 160 mg dose (group 2) achieved the predefined response 
criteria, including a reduction of ≥50% CRP values from base-
line and resolution of fever (table 3). As per the study protocol, 
five patients initially treated with 80 mg tadekinig alfa who did 
not achieve the response criteria at week 3 were up-titrated to 
receive 160 mg tadekinig alfa for an additional 12 weeks. Two 
responders, according to predefined study criteria at week 3, 
were also up-titrated: one patient from 80 mg to 160 mg and one 
patient from 160 mg to 320 mg tadekinig alfa, at the discretion of 
the treating physician. Since at least four patients in the 160 mg 
group achieved early predicted criteria of response, no patients 
were assigned to receive the higher dose based on non-response.
Figure 1 Patient disposition. *One responder and five non-responders. †One patient (responder) was up-titrated to 320 mg. AOSD, adult-onset Still’s 
disease; ISR, injection site reaction; SAE, serious adverse event.
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In patients without arthritis at baseline, clinical response was 
solely based on the results of laboratory tests. The 12-week effi-
cacy analysis was first carried out including all patients with data 
at 12 weeks of tadekinig alfa treatment (table 3). Of the four 
patients treated with tadekinig alfa 80 mg throughout the study, 
two achieved the response criteria. Of 12 patients initially treated 
table 1 Demographic and baseline characteristics of patients with AOSD treated with tadekinig alfa
All
(n=23)
80 mg (group 1)
(n=10)
160 mg (group 2)
(n=13)
Age, years 41 (30–58.5) 49.5 (34.2–58.7) 35 (30–58)
Gender (male/female) 7/16 4/6 3/10
BMI, kg/m2 25.33 (23–27.5) 24.5 (23.1–34.5) 25.4 (22.4–26.4)
Disease duration, months 15 (6.5–42.2) 25.5 (8.7–44.2) 11.6 (2.1–37.6)
No of previous flares, n (%) 
  0 7 (30.4) 2 (20) 5 (38.46) 
  1 2 (8.69) 1 (10) 1 (7.69) 
  2 5 (21.73) 2 (20) 3 (23.07) 
  ≥3 3 (13.04) 3 (30) 0 
  Unknown 6 (26.08) 2 (20) 4 (30.76) 
Baseline disease manifestations, n (%) 
  Skin rash 13 (56.52) 7 (70) 6 (46.15) 
  Arthritis/arthralgia 19 (82.6) 8 (80) 11 (84.6) 
  Swollen joints 16 (69.5) 6 (60) 10 (76.92) 
  Tender joints 18 (78.26) 8 (80) 10 (76.92) 
  SJC* 4 (0–5) 2.5 (0–4.75) 4 (3–5) 
  TJC* 6 (1–11.5) 7 (4–12) 6 (1–8) 
  Fever 2 (8.70) 0 2 (15.38) 
  Neutrophilia (>8  g/L) 14 (60.86) 5 (50) 9 (69.23) 
Comorbidities 21 (91.3) 10 (100) 11 (84.61)
Previous treatments, n (%) 
  NSAIDs 14 (65.21) 7 (70) 7 (53.84) 
  Glucocorticoids 22 (96) 10 (100) 12 (92) 
   Prednisone dose (mg/day) 30 (7.9–50) 35 (30–50) 15 (7.5–32.5) 
  csDMARDs 13 (56.5) 6 (60) 7 (53.8) 
   1 csDMARD 9 (39.1) 5 (50) 4 (30.8) 
   ≥2 csDMARDs 4 (17.4) 1 (10) 3 (23) 
Previous csDMARD therapy, n (%) 
  MTX 11 (47.82) 5 (50) 6 (46.15) 
  LFN 1 (4.3) 0 1 (7.69) 
  MMF 1 (4.3) 1 (10) 0 
  Antimalarials 3 (13) 1 (10) 2 (15.4) 
Patients with bDMARDs, n (%) 9 (39.1) 4 (40) 5 (38.5) 
  1 bDMARD 4 (17.4) 1 (10) 3 (23) 
  ≥2 bDMARDs 5 (21.7) 3 (30) 2 (15.4) 
Previous bDMARD therapy, n (%) 
  Anakinra 6 (26.08) 4 (40) 2 (15.38) 
  Canakinumab 3 (13.04) 2 (20) 1 (7.69) 
  Etanercept 2 (8.7) 1 (10) 1 (7.69) 
  Tocilizumab 3 (13.04) 0 3 (23.07) 
  Rituximab 1 (4.3) 0 1 (7.69) 
  Abatacept 1 (4.3) 0 1 (7.69) 
Concomitant treatments, n (%) 
  NSAIDs 12 (52.2) 8 (80) 7 (53.84) 
  Glucocorticoids 21 (91.30) 10 (100) 11 (84.61) 
  MTX 7 (26.08) 5 (50) 2 (15.38) 
  LFN 1 (4.3) 0 1 (7.69) 
  MMF 1 (4.3) 1 (10) 0 
Data are n/N (%) or median (IQR), unless stated otherwise.
*According to a 44-joint assessment.
AOSD, adult-onset Still’s disease; bDMARDs, biological disease-modifying antirheumatic drugs; BMI, body mass index; csDMARDs, conventional synthetic disease-modifying 
antirheumatic drugs; LFN, leflunomide; MMF, mycophenolate mofetil; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; SJC, swollen joint count; TJC, tender 
joint count.
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with 160 mg tadekinig alfa, 7 patients achieved the response 
criteria. Eight of the 18 patients who received 160 mg tadekinig 
alfa, either from the study start or after 3 weeks of treatment 
with 80 mg tadekinig alfa, achieved the response criteria at week 
12 (table 3). Both patients who up-titrated to 160 mg or 320 mg 
continued to be responders after 12 weeks. None of the non-re-
sponding patients from group 1 achieved the response criteria 
after 12 weeks of therapy with tadekinig alfa 160 mg. Of note, 
the response rate in patients with systemic manifestations but 
without synovitis (seven patients) did not differ from the whole 
group. The patient without prior glucocorticoid or DMARD 
treatment responded to tadekinig alfa (see online supplementary 
materials).
Additional secondary endpoints
Skin rash showed improvement over time versus baseline 
(figure 2), with 13/23 patients having skin rash at baseline, 
and only 6 patients at 12 weeks (P=0.02). Patient-reported 
and physician-reported outcomes also showed a general trend 
towards improvement (online supplementary table S1).
Overall, median prednisone dosage was decreased from 
12.5 mg/day at baseline to 10 mg/day at 12 weeks (P=0.01). The 
decrease in prednisone was larger among the responders at 12 
weeks with a tapering of 12.8 mg, compared with only 1 mg in 
the non-responders, although this difference was not statistically 
significant (P=0.23).
Biomarker levels decreased at week 12 compared with base-
line levels (figure 3A–I; online supplementary table S2). Serum 
levels of free IL-18 were detected in seven patients at baseline. 
Among these patients, four exhibited a clinical response. Free 
IL-18 was undetectable in all these patients at the final blood 
assessment, whereas free IL-18 remained elevated in two of three 
patients who failed to respond to tadekinig alfa. In the overall 
population, as well as in patients from group 2 and in patients 
from group 1 up-titrated to the 160 mg dosage, the levels of 
ferritin, IL-6, neutrophils, S100A8/9 and S100A12 significantly 
decreased at week 12, as compared with baseline levels. Levels 
of CRP, SAA, ferritin, IL-6, S100A8/9 and S100A12 were signifi-
cantly decreased in patients from group 2 (figure 3; online 
supplementary table S2). Elevated transaminase levels were 
present at baseline in two patients (>3-fold upper normal limits) 
and normalised with tadekinig alfa therapy in both patients.
Results of the pharmacokinetic study are reported in the 
online supplementary materials.
table 2 Most frequent AEs, >5% of the patients, by SOC and preferred term
sOC
Overall* 80 mg* 160 mg*
Patients events Patients events Patients events
ISRs 13 25 3 5 10 20
Infections/infestations 11 19 3 7 9 12
Musculoskeletal and CT disorders 9 39 3 4 8 35
Gastrointestinal disorders 8 13 1 1 8 12
Nervous system disorders† 4 8 1 1 4 7
Condition aggravated‡ 3 5 0 0 3 5
Asthaenia and fatigue 5 5 2 2 3 3
Fever 1 5 0 0 1 5
*Events were recorded according to the dose that the patient was exposed to at the moment of the event.
†Comprising headache, dysaesthesia, sciatica and tension headache.
‡A worsening of disease components that were present at the onset of the study or are components of the primary disease (comprising global aggravated condition (n=1 
patient), worsening of arthralgia or myalgia (n=1 patient), and an increase of global pain and skin rash (n=1 patient)).
AEs, adverse events; CT, connective tissue; ISRs, injection site reactions; SOC, System Organ Class.
table 3 Clinical and biological signs of response
Week 3
(80 mg)
(n=10)
Week 3
(160 mg)
(n=12)
Week 12
(80 mg)
(n=4)
Week 12
(160 mg)
(n=12)
Week 12
(160 mg)*
(n=18)
CRP reduction ≥50% 4 (40) 5 (41.7) 1 (25) 6 (50) 7 (38.9)
CRP reduction ≥70% 2 (20) 2 (16.7) 1 (25) 6 (50) 7 (36.8)
CRP normalisation (≤5 mg/L) 2 (20) 3 (25) 1 (25) 4 (33.3) 4 (22.2)
Ferritin normalisation (≤150 mg/L) 2 (20) 6 (50) 2 (50) 6 (50) 8 (38.9)
SJC44† reduction ≥20%‡ 5 (83.3) 5 (55.6) 2 (100) 8 (88.9) 10 (76.9)
TJC44† reduction ≥20%§ 7 (87.5) 4 (44.4) 2 (100) 5 (50) 8 (50)
Both joint counts reduction ≥20% 5 (83.3) 3 (37.5) 2 (100) 5 (62.5) 7 (58.3)
Responders at week 3 (1 or 3+no fever) 5 (50) 6 (50) NA NA NA
Responders at week 12 (2 or 3 or 4 and 7) N/A N/A 2 (50) 7 (58.3) 8 (44.4)
Data are n (%).
*Includes six patients who were up-titrated to the 160 mg dose and 12 patients initially included in the 160 mg group. For patients who discontinued before week 12, the data 
correspond to the last observation.
†According to a 44-joint assessment.
‡Patients with SJC44 equal to 0 at baseline were excluded since their reduction could not be computed, leaving 6 patients in group 80 mg (week 3), 10 patients in group 160 mg 
(week 3), 2 patients in group 80 mg (week 12) and 14 patients in group 160 mg (week 12).
§Patients with TJC44 equal to 0 at baseline were excluded since their reduction could not be computed, leaving 8 patients in group 80 mg (week 3), 10 patients in group 160 mg 
(week 3), 2 patients in group 80 mg (week 12) and 17 patients in group 160 mg (week 12). At week 12, four patients continued their treatment at the dose of 80 mg.
CRP, C reactive protein; NA, not applicable; SJC, swollen joint count; TJC, tender joint count.
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dIsCussIOn
This phase II clinical trial examined for the first time the safety 
and efficacy of IL-18 blockade in patients with AOSD. Most 
patients had previously used glucocorticoids; approximately half 
had received csDMARDs and one-third bDMARDs. The results 
show that tadekinig alfa at doses of 80 mg and 160 mg three 
times per week appeared to have a favourable safety profile. 
In addition, we observed early signs of clinical and laboratory 
marker efficacy with response rates of 50%, irrespective of the 
tadekinig alfa dosage in this heterogeneous population of diffi-
cult-to-treat patients.
Most of the AEs were mild and resolved after drug discontin-
uation. The 60-year-old patient in which toxic optic neuropathy 
occurred suffered from hypertension, pulmonary emphysema 
and had serious thrombotic episodes prior to study participation. 
This AE was unexpected according to results of previous clinical 
studies. The DSMB reviewed the case and questioned the physi-
cian’s conclusion that it was possibly drug related, suggesting 
that other, more likely, explanations had not been ruled out. 
The DSMB considered that there was insufficient information 
to draw any firm conclusion since there had been insufficient 
exploration to discard the diagnosis of ophthalmic vein throm-
bosis in this patient. ISRs were more frequently observed in 
patients receiving tadekinig alfa 160 mg.
The safety and efficacy of tadekinig alfa has been examined in 
two double-blinded, placebo-controlled, phase Ib clinical trials 
in 36 patients with rheumatoid arthritis and 35 patients with 
psoriasis (unpublished results). The safety profile showed that 
the most commonly reported AEs were ISRs that were mild in 
most cases. Local tolerability tended to worsen with increasing 
doses. Tadekinig alfa was administered subcutaneously at doses 
ranging from 80 mg to 350 mg three times per week based on the 
30-hour half-life of tadekinig alfa for 6 weeks. These studies did 
not show any definite signs of efficacy.
In the current study, the results at week 3 did not show any 
difference in response between 80 mg and 160 mg tadekinig 
alfa doses. Furthermore, all non-responders who were up-ti-
trated from 80 mg to 160 mg did not reach a subsequent clinical 
response. These results suggest that the tadekinig alfa 80 mg dose 
already has a meaningful clinical effect.
One patient was included despite not meeting the inclusion 
criteria of having been previously exposed to glucocorticoids, 
NSAIDS and/or csDMARDs since this case provides additional 
information on safety, our primary endpoint. This patient 
responded to tadekinig alfa without the addition of glucocor-
ticoids or csDMARDs. Most importantly, following the discon-
tinuation of tadekinig alfa at week 12, the patient experienced 
a disease flare.
Consistent with the positive effect of IL-1 or IL-6 targeting in 
SoJIA therapies, inhibition of these pathways has been studied in 
AOSD. Tocilizumab, a humanised monoclonal antibody against 
IL-6 receptor alpha, significantly reduced articular and systemic 
manifestations, acute-phase markers and prednisone dosage in 
patients with AOSD.8 In 140 patients with AOSD treated with 
anakinra, a human recombinant IL-1Ra, systemic and articular 
manifestations improved in most patients, and a glucocorti-
coid-sparing effect and a significant reduction in the number of 
patients on csDMARDs were observed.10 Our results show that 
IL-18 inhibition offers another possibility of therapy within the 
scope of anticytokine treatment for the management of AOSD.
The fact that only two patients had fever at baseline was unex-
pected. However, all patients had fever at some point during the 
disease course. It is plausible that the inclusion of some patients 
with long-standing disease may explain this observation. Some 
disease manifestations may also have been partly controlled 
by previous therapies. However, to avoid a carryover effect of 
former bDMARDs, a long washout period (ie, 6 months for 
canakinumab) was required prior to study inclusion.
Figure 2 Evolution of skin rash over time. Presented fractions show number of patients with rash at each V/total number of patients. *Four patients 
did not have V4, but had V5 or V6 (early termination V). V, visit.
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Figure 3 Evolution of serum biomarker levels by group and time point: (A) CRP; (B) ferritin; (C) IL-6; (D) neutrophil; (E) SAA; (F) S100A12; (G) 
S100A8/A9; (H) IL-1Ra; (I) TNF-alpha. Data are median (IQR). The 20 patients included in the overall group comprised 17 patients who had baseline 
values and at week 12, and 3 patients with values at week 6, but who discontinued thereafter. Three patients who discontinued at earlier time points 
were not included. Group 2 plus up-titrated group 1, n=16. CRP, C reactive protein; IL, interleukin; Ra, receptor antagonist; NS, not significant; SAA, 
serum amyloid A; TNF, tumour necrosis factor.
847Gabay C, et al. Ann Rheum Dis 2018;77:840–847. doi:10.1136/annrheumdis-2017-212608
Clinical and epidemiological research
Our study is the first prospective study examining a drug with a 
completely new mode of action in AOSD. Another strength of our 
study is the inclusion of patients with ‘difficult to treat’ disease, 
including a large percentage of patients previously treated with 
bDMARDs. Furthermore, several patients had various comor-
bidities. Thus, our findings provide important results regarding 
the safety of IL-18 targeting with tadekinig alfa in AOSD. An 
open-label design, absence of a control group and heteroge-
neity within the study population are important limitations in 
the assessment of a treatment’s efficacy. However, the clinical 
response in a group of patients with chronic disease despite the 
use of DMARDs and inclusion of objective measures, such as 
biomarkers of inflammatory responses, provide supportive data 
for treatment efficacy.
In conclusion, our results show that tadekinig alfa appears 
to have a favourable safety profile and is associated with early 
signs of efficacy in AOSD, thus warranting further clinical 
investigation.
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